Journal ArticleDOI
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Reads0
Chats0
TLDR
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.About:
This article is published in The Lancet.The article was published on 2019-07-13. It has received 1449 citations till now. The article focuses on the topics: Dulaglutide & Placebo-controlled study.read more
Citations
More filters
Journal ArticleDOI
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
Christophe De Block,Clifford J. Bailey,Carol Wysham,Andrea Hemmingway,Sheryl Allen,Jennifer C. Peleshok +5 more
TL;DR: Evidence from these clinical trials suggests that tirzepatide offers a new opportunity for effective lowering of HbA1c and body weight in adults with type 2 diabetes.
Journal ArticleDOI
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
TL;DR: In this article, the authors summarized and critically interpreted the available evidence emerging from clinical studies and suggested that the role of the kidney is crucial for the effect of SGLT-2i on the clinical outcomes not only because these drugs slowdown the time-dependent decline of kidney function and enhance the response to diuretics, but also because they attenuate the meal-related anti-natriuretic pressure (lowering postprandial hyperglycemia and hyperinsulinemia and preventing proximal sodium reabsorption), which would reduce the individual sensitivity to
Journal ArticleDOI
Pharmacotherapy of type 2 diabetes: An update and future directions.
Antea DeMarsilis,Niyoti Reddy,Chrysoula Boutari,Andreas Filippaios,Elliot Sternthal,Niki Katsiki,Christos S. Mantzoros +6 more
TL;DR: In this paper , the authors provide an updated summary of the pharmacotherapeutic approach to Type 2 diabetes (T2D) and outline an up-to-date treatment approach that starts with identification of an individualized goal for glycemic control then selection, initiation, and further intensification of a personalized therapeutic plan for T2D.
Journal ArticleDOI
Trend 2010–2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy
Gian Paolo Fadini,Vera Frison,Mauro Rigato,Mario Luca Morieri,Natalino Simioni,Federica Tadiotto,Michele D'Ambrosio,Agostino Paccagnella,Annunziata Lapolla,Angelo Avogaro +9 more
TL;DR: Despite the early positioning of GLP-1RA in T2D treatment algorithms, GLP -1RA have been prescribed in patients with progressively more advanced disease stage and especially in the presence of cardiovascular disease.
Journal ArticleDOI
Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019
Kristian Løkke Funck,Jakob S. Knudsen,Troels Krarup Hansen,Reimar W. Thomsen,Erik Lerkevang Grove,Erik Lerkevang Grove +5 more
TL;DR: To investigate temporal trends in time to initiation of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide 1 analogues (cardioprotective glucose‐lowering drugs [GLDs]) in patients with a new dual diagnosis of type 2 diabetes (T2DM) and cardiovascular disease (CVD).
References
More filters
Journal ArticleDOI
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
TL;DR: The purpose of this study was to develop an equation from MDRD Study data that could improve the prediction of GFR from serum creatinine concentration, and major clinical decisions in general medicine, geriatrics, and oncology are made by using the Cockcroft-Gault formula and other formulas to predict the level of renal function.
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
TL;DR: The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.
Andrew S. Levey,Josef Coresh,Tom Greene,Lesley A. Stevens,Yaping (Lucy) Zhang,Stephen Hendriksen,John W. Kusek,Frederick Van Lente +7 more
TL;DR: The MDRD Study equation has now been reexpressed for use with a standardized serum creatinine assay, allowing GFR estimates to be reported in clinical practice by using standardized serumcreatinine and overcoming this limitation to the current use of GFR estimating equations.
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.